# Anne Wojcicki

> Anne Wojcicki is a seed investor at Los Altos Community Investments backing Health Care. See 64 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Los Altos Community Investments](https://shizune.co/investors/profile/los-altos-community-investments)
- Location: San Francisco, United States
- Total investments: 64
- Last investment: Jun 2026
- Lead investor: 2%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/annewojcicki
- X (Twitter): https://twitter.com/annewoj23
- Facebook: https://www.facebook.com/annewoj

Anne Wojcicki is a seed investor at Los Altos Community Investments in San Francisco focused on Health Care and Medical. Anne Wojcicki is the Co-Founder and CEO of 23andMe. She previously worked at Passport Capital as a Healthcare Analyst. Anne Wojcicki attended Yale University.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1M–$12M |
| Series A | $7M–$70M |
| Series B | $19M–$63M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 35 | 55% |
| Medical | 15 | 23% |
| Biotechnology | 9 | 14% |
| Artificial Intelligence | 8 | 13% |
| Software | 7 | 11% |

94 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 19 | 30% |
| Series A | 17 | 27% |
| Series B | 12 | 19% |
| Series C | 5 | 8% |
| Pre-Seed | 3 | 5% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 50 | 78% |
| United Kingdom | 3 | 5% |
| Canada | 1 | 2% |
| Israel | 1 | 2% |
| Nigeria | 1 | 2% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Clair Health | Clair Health is a health technology company developing a wearable device that functions as a continuous, non-invasive hormone monitor designed specifically for women. | $11.6M | Seed | Jun 17, 2026 |  |
| The Invention Network | ScaleIP is an IP business intelligence platform that helps companies monetize IP. | $4M | Pre-Seed | Nov 05, 2025 |  |
| World Labs | World Labs is an AI startup that can analyze visual data with comprehension akin to a person's, a substantial advancement above existing capacities. | $230M | Venture - Series Unknown | Sep 13, 2024 |  |
| Solace | Solace is a digital health platform that connects patients with expert healthcare advocates. Their health advocates are former doctors, nurses, pharmacists, and other clinical and experience-driven professionals who navigate patients through healthcare challenges. | $14M | Series A | Aug 22, 2024 |  |
| Endo Health | Endo Health creates a gamified "AI endocrinologist" for type 2 diabetes management. They are creating a pleasant AI medical assistant that will walk patients through every stage of diabetic control, complete with gamified involvement. | $1M | Pre-Seed | Jun 25, 2024 |  |
| Gameto | Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives.Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. Gameto aims to changethat.Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, they have developed a platform to produce female reproductive cell lines. They use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones. Their team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases. Gameto's first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno. | $33M | Series B | May 29, 2024 |  |
| Midi Health | Midi Health provides virtual healthcare services focused on midlife women’s health, especially around hormonal changes such as perimenopause and menopause, through personalized care plans delivered by clinicians trained in these areas. Its services include telehealth consultations that can integrate prescription support, supplements, lifestyleguidance, and symptom-specific treatments to address issues like weight, mood, sleep, and sexual wellness. Midi Health also offers tailored support protocols that consider an individual’s health history and goals to guide ongoing care. Its platform makes care accessible online and works with insurance for coverage of visits and prescriptions. The company additionally offers targeted supplements designed to complement its clinical care approach. | $63M | Series B | Apr 24, 2024 |  |
| Brightside Health | Brightside Health is a mental health care company that helps employees better navigate and manage their financial well-being. The company makes it simple and affordable to get expert, personalized treatment for depression and anxiety all from the comfort of home. Their mission is to help people lead healthy, vital, and productive lives by making iteasy and affordable to get high-quality depression and anxiety care.Brightside was founded in 2017 and is headquartered in San Francisco, California, United States. | $33M | Series C | Mar 26, 2024 |  |
| Ezra AI | Ezra has created a new way to screen for cancer using full-body MRI technology assisted by Artificial Intelligence. The company's first AI, developed to assist radiologists when interpreting MRI images of the prostate, is an FDA-cleared software as a medical device. | $21M | Series B | Feb 07, 2024 |  |
| Orchid | Orchid is a reproductive technology startup that is capable of detecting rare genetic disorders. Orchid’s preconception system analyzes both partners’ genomes and assesses genetic predispositions to common diseases, including heart disease, stroke, schizophrenia, Alzheimer’s disease, breast cancer, and diabetes. Orchid results are developed withworld-class experts in reproductive medicine and genetics to give its clients the most accurate results.Orchid offers a “Couple Report” that utilizes an at-home saliva test to analyze each person’s genomes to detect the probability of genetic risks, then models how their DNA together will combine in a future child. If elevated risk is detected, Orchid provides insights to help couples monitor biomarkers, adapt their diet or elect for procedures, such as in vitro fertilization. It was founded by Noor Siddiqui in 2019 and is headquartered in San Francisco, California. | $12M | Seed | Dec 05, 2023 |  |

10 of 64 investments shown.

## Co-investors
- [Portfolia](https://shizune.co/investors/profile/portfolia) — VC Fund, 6 deals together
- [S32](https://shizune.co/investors/profile/section-32) — VC Fund, 6 deals together
- [Y Combinator](https://shizune.co/investors/profile/y-combinator) — VC Fund, 6 deals together
- [Khosla Ventures](https://shizune.co/investors/profile/khosla-ventures) — VC Fund, 5 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 5 deals together
- [Able Partners](https://shizune.co/investors/profile/able-partners) — VC Fund, 4 deals together

## About Los Altos Community Investments

VC Fund · Los Altos, United States

Los Altos Community Investments provides real estate funding and community development services for the Los Altos community.

1 contacts available at Los Altos Community Investments.

| Name | Title | Profile |
| --- | --- | --- |
| Anne Wojcicki | CEO, Principal and Founder | https://shizune.co/investors/profile/anne-wojcicki |

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [OurCrowd](https://shizune.co/investors/profile/ourcrowd) — VC Fund
- [Entrée Capital](https://shizune.co/investors/profile/entree-capital) — VC Fund
- [Pitango VC](https://shizune.co/investors/profile/pitango-venture-capital) — VC Fund

## Featured in investor lists
- [Health Care Angel Investors](https://shizune.co/investors/health-care-angel-investors)
- [Health Care Angel Investors in United States](https://shizune.co/investors/health-care-angel-investors-united-states)
- [Medical Angel Investors](https://shizune.co/investors/medical-angel-investors)
- [Medical Angel Investors in United States](https://shizune.co/investors/medical-angel-investors-united-states)
- [Community Angel Investors](https://shizune.co/investors/community-angel-investors)
- [Community Angel Investors in United States](https://shizune.co/investors/community-angel-investors-united-states)

## FAQ

### What does Anne Wojcicki invest in?

Anne Wojcicki invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Series A stage. Most of the 64 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Anne Wojcicki's check size?

Anne Wojcicki typically joins rounds of $1M–$12M at Seed, $7M–$70M at Series A and $19M–$63M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Anne Wojcicki participates in.

### When did Anne Wojcicki last invest?

The most recent investment recorded for Anne Wojcicki closed in Jun 2026. Shizune tracks 64 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co